Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 15,000 shares of the business’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $114.41, for a total value of $1,716,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ NBIX opened at $106.56 on Wednesday. Neurocrine Biosciences, Inc. has a twelve month low of $67.32 and a twelve month high of $126.98. The company has a quick ratio of 9.19, a current ratio of 9.19 and a debt-to-equity ratio of 1.00. The stock has a market cap of $10.48 billion, a P/E ratio of -65.78, a price-to-earnings-growth ratio of 37.22 and a beta of 0.94.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The business had revenue of $151.80 million during the quarter, compared to analysts’ expectations of $151.51 million. During the same quarter in the previous year, the firm earned ($0.13) EPS. The firm’s revenue was up 149.7% compared to the same quarter last year. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 0.15 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. increased its stake in Neurocrine Biosciences by 643.7% during the second quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after acquiring an additional 972 shares during the period. TRUE Private Wealth Advisors bought a new position in Neurocrine Biosciences during the third quarter valued at about $127,000. Steward Partners Investment Advisory LLC bought a new position in Neurocrine Biosciences during the third quarter valued at about $127,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Neurocrine Biosciences by 103.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock valued at $167,000 after acquiring an additional 1,025 shares during the period. Finally, Financial Architects Inc increased its stake in Neurocrine Biosciences by 283.7% during the third quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock valued at $170,000 after acquiring an additional 1,024 shares during the period.
A number of analysts have weighed in on NBIX shares. Needham & Company LLC set a $125.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $162.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, August 1st. Oppenheimer set a $128.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Jefferies Financial Group boosted their price target on Neurocrine Biosciences to $124.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Finally, BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, July 27th. One analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $124.88.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://theenterpriseleader.com/2018/11/07/insider-selling-neurocrine-biosciences-inc-nbix-director-sells-15000-shares-of-stock.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Read More: What are the benefits of a balanced fund?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.